These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 20673774)

  • 1. Structure-based drug discovery and protein targets in the CNS.
    Hubbard RE
    Neuropharmacology; 2011 Jan; 60(1):7-23. PubMed ID: 20673774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From purified GPCRs to drug discovery: the promise of protein-based methodologies.
    Alkhalfioui F; Magnin T; Wagner R
    Curr Opin Pharmacol; 2009 Oct; 9(5):629-35. PubMed ID: 19443270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Native MS: an 'ESI' way to support structure- and fragment-based drug discovery.
    Vivat Hannah V; Atmanene C; Zeyer D; Van Dorsselaer A; Sanglier-Cianférani S
    Future Med Chem; 2010 Jan; 2(1):35-50. PubMed ID: 21426045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligand specificity, privileged substructures and protein druggability from fragment-based screening.
    Barelier S; Krimm I
    Curr Opin Chem Biol; 2011 Aug; 15(4):469-74. PubMed ID: 21411360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in fragment-based lead discovery.
    Schulz MN; Hubbard RE
    Curr Opin Pharmacol; 2009 Oct; 9(5):615-21. PubMed ID: 19477685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. G-protein-coupled receptor-focused drug discovery using a target class platform approach.
    Heilker R; Wolff M; Tautermann CS; Bieler M
    Drug Discov Today; 2009 Mar; 14(5-6):231-40. PubMed ID: 19121411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key factors for successful generation of protein-fragment structures requirement on protein, crystals, and technology.
    Böttcher J; Jestel A; Kiefersauer R; Krapp S; Nagel S; Steinbacher S; Steuber H
    Methods Enzymol; 2011; 493():61-89. PubMed ID: 21371587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automated protein-ligand crystallography for structure-based drug design.
    Mooij WT; Hartshorn MJ; Tickle IJ; Sharff AJ; Verdonk ML; Jhoti H
    ChemMedChem; 2006 Aug; 1(8):827-38. PubMed ID: 16902937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational methodologies for compound database searching that utilize experimental protein-ligand interaction information.
    Tan L; Batista J; Bajorath J
    Chem Biol Drug Des; 2010 Sep; 76(3):191-200. PubMed ID: 20636330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent applications of protein crystallography and structure-guided drug design.
    Williams SP; Kuyper LF; Pearce KH
    Curr Opin Chem Biol; 2005 Aug; 9(4):371-80. PubMed ID: 16006182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SHOP: a method for structure-based fragment and scaffold hopping.
    Fontaine F; Cross S; Plasencia G; Pastor M; Zamora I
    ChemMedChem; 2009 Mar; 4(3):427-39. PubMed ID: 19152365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico carborane docking to proteins and potential drug targets.
    Calvaresi M; Zerbetto F
    J Chem Inf Model; 2011 Aug; 51(8):1882-96. PubMed ID: 21774557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virtual screening for lead discovery.
    Tang YT; Marshall GR
    Methods Mol Biol; 2011; 716():1-22. PubMed ID: 21318897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lead generation and examples opinion regarding how to follow up hits.
    Orita M; Ohno K; Warizaya M; Amano Y; Niimi T
    Methods Enzymol; 2011; 493():383-419. PubMed ID: 21371599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Form follows function: shape analysis of protein cavities for receptor-based drug design.
    Weisel M; Proschak E; Kriegl JM; Schneider G
    Proteomics; 2009 Jan; 9(2):451-9. PubMed ID: 19142949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docking and scoring in virtual screening for drug discovery: methods and applications.
    Kitchen DB; Decornez H; Furr JR; Bajorath J
    Nat Rev Drug Discov; 2004 Nov; 3(11):935-49. PubMed ID: 15520816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.